LataMed AI Corp. (LMED)

Price$0.3800Cached quoteAs of 2026-09-11 20:45 UTC

AI: Overvalued

Price checkThe market value looks rich versus a pre-revenue balance sheet dominated by acquired intangible assets.

Using the post-split share count implied by the SEC filings, the observed quote implies roughly $86.7 million of equity value. At June 30, reported stockholders’ equity was about $7.1 million and total assets were $7.8 million, entirely intangible, while revenue was zero. That is roughly 12 times book equity. With no earnings or sales, P/E and price-to-sales are not useful; investors are mostly paying for successful future commercialization.

Big pictureCash durability is the central risk because operations currently depend on new financing rather than customers.

At June 30 the company reported no cash, no current assets, and $771,081 of current liabilities, creating the same-sized working-capital deficit; working capital measures near-term assets minus near-term obligations. First-half operating cash use was $83,418 and was matched by new note borrowings. Notes of $355,722 plus $88,042 of related-party notes carried 10% interest and were due on demand, alongside $34,591 of convertible notes. This is a fragile liquidity position.

Business strengthPotentially useful healthcare software and public-sector access exist, but commercialization evidence remains early and unproven.

The business is still development-stage, but there are real assets and early commercial routes: acquired healthcare-related intellectual property, a mobile app approaching submission, and agreements or collaborations in Venezuelan healthcare. The September public-sector framework could become an important proof point if deployment reaches actual users and eventually generates paid licenses or services. The company is less tied to normal economic cycles than industrial firms, but it is exposed to government procurement timing, technology adoption, regulation, and the boom-bust cycle of microcap financing.

What could change the storyA better valuation needs paid adoption and durable financing; continued pre-revenue funding pressure would weaken the case.

Bull case: over the next 12-24 months, app launch and government or partner pilots convert into recurring paid contracts, financing arrives on reasonable terms, and software-like margins emerge. Bear case: announcements remain non-revenue, implementation slips, or funding requires repeated equity issuance. The company reported issuing 12 million common shares for acquired intangibles, exchanged 20 million common shares for 5 million nonconvertible Series C preferred shares carrying 20 votes each, then completed a 5-for-1 split and raised authorized common shares proportionally to 3.5 billion. A split alone does not dilute ownership; future issuance can.

AI: News

Public-health deployment frameworkVenezuelan science and health ministries agreed to coordinate a La Guaira rollout and evaluation.

On September 9, LataMed AI said its Venezuelan affiliate signed a cooperation framework with the two ministries. The initial plan targets ambulatory and emergency settings, covering appointment and queue management, AI-assisted preliminary triage, and emergency-response functions. Source materials cited 12 initial nodes and potential reach above 85,000 people, but the company stressed those are targets, not guaranteed deployment or revenue.

Mobile app nears releaseThe company said final testing was underway before planned submissions to Apple and Google app stores.

On August 19, LataMed AI said its mobile healthcare application had entered final testing, optimization, and deployment preparation. Management expected submission to the Apple App Store and Google Play in the coming weeks, subject to platform review and technical requirements. The app is intended as a user-facing access point for healthcare services and future AI-supported tools, but public availability and commercial adoption were not yet confirmed.

Quarterly filing flags liquidityThe June-quarter filing showed no revenue or cash and repeated substantial going-concern doubt.

On August 11, the company filed its June-quarter 10-Q: quarterly net loss was $87,408, first-half loss was $140,221, revenue and cash were both zero, and current liabilities were $771,081. Management said there was substantial doubt about the company’s ability to continue as a going concern, meaning it may not sustain normal operations without additional financing. First-half operating cash use was fully funded by new notes.

Split and ticker resetAfter a five-for-one forward split, shares returned from temporary LMEDD to permanent LMED trading.

On July 15, the split became effective after FINRA processing, multiplying each existing common share into five while leaving proportional ownership unchanged. On August 11, the temporary LMEDD symbol expired and the stock resumed LMED on OTC Markets. The related Nevada filing also increased authorized common shares to 3.5 billion, giving the company substantial capacity for future issuance, though authorization itself is not dilution.

Loading local price history

Revenue

2023

2024

2025

Net income

2023

2024

2025

Free cash flow

No reported data

Total cash / debt

CashTotal debt

2023

2024

2025

Financial statements

	2025	2024	2023
Revenue	$0	$0	$0
Operating expenses	$171,852	$3.3M	$828,927
Operating income	−$171,852	−$3.3M	−$828,927
EBITDA	−$171,852	−$3.2M	−$1.7M
Net income	−$207,485	−$3.3M	−$1.7M
Basic EPSper basic share	-$0.00	-$0.02	-$1.80
Diluted EPSper diluted share	-$0.00	-$0.11	-$0.02